Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Clinical trial NCT03834493 · COMPLETED
Trial details
- NCT number
- NCT03834493
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-28
- Primary completion
- 2022-12-12
- Enrollment
- 1244
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.